Literature DB >> 25495251

Endovascular treatment of Budd-Chiari syndrome with hepatic vein obstruction in China.

Hong-Fei Sang1, Xiao-Qiang Li.   

Abstract

UNLABELLED: Abstract Purpose: To evaluate characteristics of obstructions of the hepatic veins (HVs) in Chinese patients, technical aspects of puncture of the HVs, short- and mid-term outcomes, and complications of endovascular treatment. PATIENTS AND METHODS: Forty-eight HV patients with different degrees of symptoms and signs of portal hypertension were enrolled in our study. Endovascular treatments with balloon and stents were performed. Catheter-directed thrombolysis (CDT) was performed in patients with thrombosis in the HVs. For patients with lesions of both the HVs and the inferior vena cava (IVC), balloon expansions or stenting were performed at the IVC lesions also.
RESULTS: Endovascular treatments were successful in 43 patients. The technically success rate was 89.6% (43/48). Fifteen patients underwent solely balloon expansions, 28 patients had balloon expansions and stentings, 5 patients underwent CDT, and 3 patients had implanted stents in the IVC lesions at the same time. The symptoms of portal hypertension were alleviated in 39 patients postoperatively. In the other 4 cases portal hypertension was mildly alleviated at discharge. Thirty-nine of the 43 patients were followed up for an average of 24±1.3 months (range, 6-62 months). Ascites were completely resolved in 32 cases, with a small amount of ascites in 4 patients and moderate to massive amounts in 3 patients. Hepatomegaly and splenomegaly completely disappeared in 30 patients and still could be touched in 6 patients. The HVs were patent in 29 patients. Restenosis and re-occlusion of the HVs appeared in 4 cases. All patients were successfully treated by endovascular treatments.
CONCLUSIONS: Endovascular treatments for patients with obstruction of the HVs have a high technical success rate, fewer complications, and better short- and mid-term clinical outcome. The key to successful endovascular treatment is successful puncture of HVs. For patients who have occlusive lesions of HVs combined with occlusive IVC, recanalization of the lesions of the HVs could achieve good results.

Entities:  

Mesh:

Year:  2014        PMID: 25495251     DOI: 10.1089/lap.2014.0095

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  7 in total

1.  Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome.

Authors:  Zhong-Ke Chen; Jing Fan; Chi Cao; Yu Li
Journal:  Radiol Med       Date:  2018-05-31       Impact factor: 3.469

2.  Endovascular stenting of the inferior vena cava in a patient with Budd-Chiari syndrome and main hepatic vein thrombosis: a case report.

Authors:  Young-In Yoon; Shin Hwang; Gi-Young Ko; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Young-Sang Lee; Sung-Gyu Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2015-02-28

3.  Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.

Authors:  Yan-Feng Cui; Yu-Fei Fu; De-Chun Li; Hao Xu
Journal:  Hepatol Int       Date:  2015-10-23       Impact factor: 6.047

4.  Excellent long-term outcomes of endovascular treatment in budd-chiari syndrome with hepatic veins involvement: A STROBE-compliant article.

Authors:  Yonghua Bi; Hongmei Chen; Pengxu Ding; Pengli Zhou; Xinwei Han; Jianzhuang Ren
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

5.  Outcomes of endovascular interventional therapy for primary Budd-Chiari syndrome caused by hepatic venous obstruction.

Authors:  De-Lei Cheng; Nan Zhu; Hao Xu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

6.  Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes.

Authors:  Aboelyazid Elkilany; Mohamed Alwarraky; Timm Denecke; Dominik Geisel
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

7.  Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis.

Authors:  Gauri Mukhiya; Xueliang Zhou; Xinwei Han; Dechao Jiao; Gaurab Pokhrel; Yahua Li; Sita Pokhrel
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.